2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06G.05 Molecular Characteristics of Pulmonary Lymphoepithelioma-Like Carcinoma in the Chinese Population

EP.06G.05 Molecular Characteristics of Pulmonary Lymphoepithelioma-Like Carcinoma in the Chinese Population

Pdf Summary

Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of non-small cell lung cancer with better clinical outcomes, typically affecting young, non-smoking Asians and often linked to Epstein–Barr virus (EBV) infection. Given PLELC's rarity, its molecular characteristics are not well-defined, potentially limiting treatment approaches.<br /><br />This study analyzed the next-generation sequencing data of tumor tissue samples from 26 Chinese PLELC patients over three years. The median age of patients was 48.5 years, and 69.2% were female. Results showed that 61.5% of patients had genetic alterations. These alterations primarily consisted of copy number variations (CNVs) and single nucleotide variations (SNVs). High-frequency genetic alterations involved the 11q13 amplicon (including CCND1/FGF19/FGF4/FGF3), KRAS, and CCND2, each observed in 11.5% of the cases. SNVs were present in genes such as TP53, CYLD, CBFB, NRAS, AXIN1, PIK3CA, BMPR1A, and NFKBIA in 34.6% of patients. One patient exhibited a germline pathogenic deletion mutation in BAP1 without corresponding somatic mutations, highlighting the importance of germline mutation screening for cancer risk evaluation. No microsatellite instability was detected, and 84.6% of patients were EBV positive.<br /><br />The study concludes that there is a notable presence of CNVs in the 11q13 region, as well as KRAS and CCND2 genes in PLELC cases. Understanding these molecular characteristics can enhance the comprehension of PLELC’s biology, aiding in more accurate diagnosis and targeted treatment for this rare cancer type.

Asset Subtitle

Wenyan Yu

Meta Tag

Speaker Wenyan Yu

Topic Pathology and Biomarkers

Keywords

Pulmonary lymphoepithelioma-like carcinoma

PLELC

non-small cell lung cancer

Epstein–Barr virus

next-generation sequencing

genetic alterations

copy number variations

single nucleotide variations

11q13 amplicon

targeted treatment